Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more systems associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are al so disclosed.
